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Background and aims: Atherosclerosis is a vessel disease, having a relatively early onset and 
a slow progression, and is currently the first cause for morbidity and mortality worldwide. 
Patients with atherosclerosis are usually classified according to their cardiovascular risk; 
however, tools to characterize the atherosclerotic plaque or to predict its progression are 
presently missing. In this thesis, we present a novel approach to this issue, by applying 
multimodal (CT- ad PET-based) imaging, in synergy with segmentation analysis, to the 
atherosclerotic plaques. 
Materials and Methods: Patients were recruited from three different databases 
retrospectively and then assigned to three different study populations. Population A 
consisted of 51 patients (19 females, mean age 699 years, range 49-82), submitted to 18F-
NaF-PET/CT (NaF-PET). Each patient underwent at least 2 Naf-PET, spaced on average 14 
months apart. In each patient, a VOI was placed on each visible CT plaque, using a CT-iso-
contour approach; mean blood-pool normalized SUV (TBR), mean HU and Agaston-like 
calcification score (CS) were computed. TBR was compared with the mean percent variation 
of HU and CS, normalized for elapsed time between NaF-PETs (NDHU% and NDCS%, 
respectively). Whole-aorta TBR was then compared to whole-aorta NDCS%. 
Population B included 79 patients (51 women, 70.8 ±8 years) who underwent NaF-PET. 
Plaque analysis was performed as described above. An in-house software application was 
used to identify and segment the trabecular bone semi-automatically. TBR and HU of 
trabecular bone were compared to the ones of arterial plaques. 
Population C consisted of twenty-seven patients (12 males, mean age 69.4 ± 8, range 56-87), 
who underwent a 18F-FDG and a 68Ga-DOTATOC PET/CT within a two-weeks period. 
Cardiovascular risk score was estimated in all patients; TBRmax and TBRmean was calculated 
in a large VOI, placed on the aorta, in FDG and DOTATOC scans. 
Results: In population A, mean HU and CS significantly increased from the first to the second 
PET/CT (p<0.001). A tight and direct correlation was noted between TBR in the plaques in 
the baseline PET and both NDHU% (R=0.67, p<0.01) and NDCS% (R=0,7, p<0.001). Whole-
aorta TBR correlated with NDCS% in the entire vessel (R=0,85, p<0.001). 
In the population B, mean plaque density showed an inverse association with vertebral HU 
density (R=-0.56, p<0.01). Plaque and trabecular bone TBR were directly and closely 
correlated (R=0.63 and p<0.001). At univariate analysis, mean HU density of aortic plaque 
was not predicted by any of the cardiovascular risk factor or by age; conversely, it was 
related to its own TBR (p=<0.001) as well as by trabecular bone TBR. 
In population C, the mean of TBRmax was significantly higher in 68Ga-DOTATOC PET, 
when compared to FDG (5,7±3,1 Vs. 2±1,2, p<0.01). A tight and direct correlation was 
noted between FDG TBRmean and CV risk score (R=0.82, p<0.001), as well as between 
68Ga-DOTATOC TBRmean and CV risk score (R=0.81, p<0.001). Average TBRmax of 
68Ga-DOTATOC was slightly higher in DM patients when compared to the non-diabetic 
ones (6±2.1 Vs. 4,9±0,9, p<0.05). 
Conclusions: PET/CT with NaF can predict subsequent plaque evolution: in particular, 
plaque displaying a higher uptake have a greater progression of calcification at follow-
up. Observing the behavior of skeletal bone might represent a new window for assessing 
the plaques´ characteristics. Inflammation within the plaque can be detected by 18F-FDG 
and by 68Ga-DOTATOC, the latter tracer might perform better, especially in diabetic 
patients. Overall PET techniques could display a great relevance in diverse research 
fields, such as assessment of therapy effectiveness and identification of vulnerable 
plaques; further study could allow the application of this methods to larger population, 
possibly enabling a patient-centered treatment and improving therapy outcomes as well 
as quality of life. 
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Cardiovascular disease: the size of the phenomenon 
One of the most abused incipits of each cardiovascular research item is the constant 
reference to the sky-rocketing prevalence of cardiovascular (CV) disease. However, this 
statement is to this day true, even though its prevalence in western countries is somewhat 
reaching a plateau [1]. When morbidity and mortality of cardiovascular and cerebrovascular 
diseases are considered as one entity, their social and economic burden exceeds by far the 
one caused by all neoplastic diseases combined [2; 3]. To size the phenomenon up, one must 
consider that CV disease, as reported by the Global Burden of Disease Study 2015, accounts 
for about 23 millions of deaths and roughly 500 millions of disability-adjusted life years 
globally. Among these events, two third are caused by cardiovascular, and one third is 
caused by cerebrovascular accidents. A complete overview of the statistics, adjustable for 
the various parameter of the global population, can be found online, using a practical search 
tool: https://gbd2016.healthdata.org/gbd-search/.  
 Moreover, the incidence and prevalence of CV disease might further increase in the years to 
come, when appropriate measures are not implemented [4]. Even though many health-
related indicators are bound to improve in the near future, some of them, such as BMI, are 
currently progressively worsening and might contribute to aggravating the disease burden in 
the aging population. 
It is evident that such a condition represents one of the most significant challenges of the 
present-day medicine: reducing the impact of CV disease could contribute to limit the huge 
cost due to the required healthcare and the years of disability [5]. Moreover and more 
importantly, the magnitude of the problem is not currently matched by an appropriate 
volume, quality and methodology of clinical research, as a large part of the available 
evidence derives from small-scale retrospective studies, with insufficient statistical power to 
guide a translational approach to the CVD pathology [6]. 
 
The cardiovascular patient: a black box of risk factors 
Since the dawn of modern internal medicine, the prevention of CVD progress has been 
focused on treating cardiovascular (CV) risk factors [7]. These factors classically include 
increased body mass index, hypertension, elevated cholesterol levels, impaired glucose 
tolerance or diabetes, and smoking habit; family history for CVD also plays a role [8]. 
Together, presence and degree of these indices concur to profile the risk for an acute 
cardiovascular event that a given patient faces [9]. This score represents the likelihood of an 
acute event, based on the patient’s clinical characteristics: it does not tell the physician 
whether an underlying cardiovascular disease is present or whether a known CV condition is 
progressing. A patient with a high CVR might live to the end of her or his days without any 
cardiological problem or might die from another cause; conversely, a patient with low risk 
might face an acute event, which could affect his or her future quality of life. To complicate 
the matter, some acute events could occur without symptoms, especially in diabetic patients 
[10] [11]. The task of the clinician is to treat the existing risk factors at the best of his or her 
possibilities; however, the uncertainty about the patients’ compliance and the relative 
difficulty to evaluate the underlying pathology complicate the prevention of CV events. This 
last point must be described in detail. 
 
The arterial plaque: a life-long history 
 
Cardiovascular disease is characterized by the progressive narrowing of blood vessels, which, 
at first, might produce symptoms only during the phases of maximal flow, such as exercise; 
later on, the stenosis might get so advanced to restrict blood flow even at rest [12]. This 
phenomenon is caused by the insurgency and the progression of the atherosclerotic plaque, 
which develops in the inner vessel intima and slowly grows towards the center of the 
vessels, causing the above-mentioned progressive obstruction [13]. The process of 
atherosclerotic formation is not a rapid one. Although cardiovascular and cerebrovascular 
diseases are ailments of the elderly, there is a large body of evidence indicating that the 
activity of plaque build-up begins at an early age. In particular, studies that were carried out 
on members of the US armed forces that have perished in combat at an early age (mean 
25.9 years) revealed a relevant prevalence (8.5%) of coronary atherosclerosis; 2.3% of all 
soldiers presented an advanced coronary artery disease [14]. Evidence of beginning 
atheromatosis has been found in the pediatric population as well [15]. These data depict an 
upsetting picture: if the cardiovascular disease is so widespread, how can the physician 
recognize the progressing CVD and adopt adequate countermeasures? 
 
The diagnostic arsenal: from electrophysiology to invasive diagnostic 
Having defined a patient as a CV risk-bearer, which steps are to be taken in order to properly 
diagnose a significant CVD? Patients presenting at least an intermediate risk for 
cardiovascular disease should receive further testing. In particular, those with intermediate 
risk benefit from non-invasive testing, such as stress EKG [16]. This test is performed by 
having the patient exercise, using a treadmill or an bicycle ergometer, or by inducing 
vasodilation with a pharmacologic agent: these measures cause an increase in the blood 
flow in normal vessels. Conversely, in vessels affected by atherosclerosis, the flow is reduced 
(as the vasodilation in healthy vessels induces the so-called “coronary steal syndrome”). The 
reduced perfusion produces ischemic damage in the affected area: this alteration 
perturbates the electrical conduction of the heart contraction impulse; which is picked up by 
the EKG device and might be revealed as an alteration of the ST-segment. Stress testing is 
reasonably safe and can be coupled to imaging, such as echocardiography or radioisotope 
perfusion imaging; however, the present a suboptimal sensitivity of 70% and a low specificity 
of 50-70% [17]. This means that a relevant proportion of patient with CAD will not be 
correctly diagnosed and that an even greater proportion will be sent to invasive imaging for 
no reason. These figures can be improved by coupling the stress test with radioisotope 
perfusion imaging [18], where a radioactive tracer is injected at the exercise peak and under 
rest condition: comparison of the two image sets allows identifying areas of reduced 
myocardial perfusion under an increased workload. Nuclear imaging offers a multiparameter 
examination, being able to estimate heart perfusion and contractility within a single 
examination; however, it is not able to provide information about the presence and 
characteristics of the underlying plaque pathology. 
Patient with a high risk for CVD or patients that test positive at first-line screening must 
undergo an invasive procedure, e.g., coronarography. This examination is performed by 
guiding an arterial catheter to the origin of the coronary arteries; here, a bolus of contrast 
medium is repeatedly injected under x-ray imaging, granting a vision of the coronary tree 
and an estimation of the blood flow. The advantages of this procedure include high 
sensitivity and the possibility to perform a therapeutic procedure (such as balloon dilation or 
stenting); the disadvantage include a non-neglectable risk for complication and the 
impossibility to visualize, under basal conditions, the arterial plaque directly [19; 20]. 
Other non-invasive methods are based on detection of plaque and luminal stenosis using x-
ray computed tomography (CT). Basically, non-enhanced CT can be used to detect calcium 
deposition within the coronary arteries, as these deposits are associated with plaques and 
present a high, bone-like attenuation coefficient [21]. Coronary calcium score (CS), which is 
obtained through an algorithm, applied on CT images, can predict the risk of major adverse 
cardiovascular events (MACE) [22]. However, it is unable to tell whether an individual plaque 
is about to rupture, and it grants no information on the degree of stenosis, perfusion, and 
coronary flow reserve. Such information may be obtained from CT-angiography, which is 
superior to CS determination in forecasting the MACE likelihood [23]. Nevertheless, its 
greatest value lays in its high negative predictive value; positive scans have however to be 
confirmed by invasive coronarography [24]. 
Overall all these electrophysiological, radiological and radioisotope methods are very 
effective in describing the effects of atherosclerosis on the cardiovascular system but offer 
little or no information on the primary cause of the CVD, i.e. the atherosclerotic plaque. 
 
The plaque microcosm: a matter of paramount importance in predicting MACE 
The matter of plaque composition is in no way a trivial one [25]. In fact, despite the large 
prevalence of atherosclerosis, only a percentage of individual will face an acute event [26]. It 
has been demonstrated that is not the present or the extent, but rather the composition of a 
plaque which determines the risk for MACE [27]. The plaque represents a tiny universe of 
complex interactions between different cells types, risk factors, and genetic predisposition: 
this complexity account for the difficulty to establish the risk purely through mere 
morphological imaging [28]. The pathophysiology of the arterial plaque development has 
been already widely and thoroughly described, with the first reports being over 150 years 
old [29]. Briefly, the process is usually started by LDL migrating into the sub-endothelium; 
here an oxidation process is started, which in turn releases cytokines and growth factors that 
attract monocytes [30]. “Foam” cells start accumulating and smooth muscle cells proliferate, 
constituting the core of the growing plaque [31]. In parallel, the chronic inflammation 
triggers a differentiation path in mesenchymal progenitors, which become committed to the 
osteoblast line; the same mechanisms produce an osteoclast differentiation from 
hematopoietic stem cells [32]. These mechanisms ultimately produce the plaque 
calcification, which is then apparent at CT imaging and that is associated with end-stage 
plaque evolution. In fact, these mechanisms are prevalent in the earlier phases of plaque 
evolution. When the calcifications progress, then the plaque becomes hypocellular and the 
calcium deposition might further progress only with “passive” mechanism, as the 
endothelium gets no longer able to impede calcium salt precipitation [33]. Under certain 
conditions, the plaque might rupture, its core might become exposed and trigger a cascade 
of coagulation phenomena [34]. 
 
Classifying the plaques’ behavior: the role of hybrid imaging  
Since the plaque represents an active, ever-changing microenvironment, it follows that 
employing morphological imaging techniques might, at best, succeed in obtaining a snapshot 
of a certain moment in the plaque history. However, no data on the plaque tendency to 
growth, or on the likelihood to cause an acute event will be obtained. 
In recent years, the question has been however tackled by hybrid (morphological and 
radioisotope) imaging. The progress made with PET/CT devices has allowed combining the 
anatomic information with the functional one, with an unprecedented spatial resolution. 
Many aspects of the plaque have been investigated up to this day. The first studies dealt 
with the identification of plaque inflammation, using 18F-fluorodeoxyglucose (FDG) as a 
tracer [35; 36]. However, FDG presents some limitations, the most important of which is the 
intensive uptake within the myocardium, which reduces the possibility to obtain accurate 
readings from plaques adjacent to the myocardial wall [37]. Other limitations include statin 
treatment and diabetes mellitus. Therefore, the possibility to investigate inflammation with 
somatostatin-receptor tracers was explored. In fact, activated macrophages express these 
receptors on their surface: this feature should be much more specific than mere glucose 
consumption as measured by FDG-PET [38]. Using 68Ga-DOTATATE, Tarkin and colleagues 
managed to identify “culprit” arteries after acute myocardial or cerebrovascular events; 
moreover, tracer uptake correlated with the cardiovascular risk score. However, another 
paper, which conducted an analysis of 68Ga-DOTATATE uptake within plaques two days 
after an acute carotid event, found no difference between culprit and non-culprit plaques 
[39]. The discrepancy might be caused by the different sample size or by the different phase 
of activation of the macrophages within the plaque. 
Inflammation represents, in fact, an intermittent phenomenon. Conversely, whereas 
calcification shows a later onset, it might indeed show a steadier progression that may allow 
the identification of the increased metabolism associated with plaque reparation after an 
acute event. For this reason, a great number of studies dealing with plaque uptake of 18F-
Natrium fluoride (NaF) have been conducted in the last decade [33; 40-45]. These studies 
demonstrated the feasibility of the method and the correlation of fluoride uptake with 
cardiovascular risk factors; moreover, they also demonstrated that such PET imaging shows 
the greatest effectiveness in plaques displaying light to moderate calcification (as the old, 
clumped calcium deposits have not enough cellularity to exhibit an adequate tracer uptake). 
Finally, a brilliant study from Joshi and co-worker demonstrated that NaF localizes into the 
culprit plaque after a MACE; the bone-seeking agent also shows a correlation with bone-
forming factors within the plaque [46]. 
In general, analyses conducted with PET tracers tried to clarify first whether tracking plaque 
metabolism was feasible and then whether plaque with suspect features could be identified. 
The first point has been doubtlessly a success: signal from the atherosclerotic lesion can be 
identified and quantified with a number of tracers, thanks to the improved acquisition and 
reconstruction protocols for PET imaging. However, the significance of this information has 
not yet been established. This point is fundamental for translational purposes, i.e. moving 
the plaque analysis to bedside. In order to do so, one has to identify a possible impact of 
plaque uptake on the disease’s progress. 
In this doctoral thesis, a longitudinal analysis of PET uptake within plaque will be carried out, 
so as to identify whether plaque uptake reflects the future plaque evolution. To this 
purpose, serial PET will be analyzed, to measure the modifications in plaque density and 
tracer uptake over time. Furthermore, regions of increased uptake without visible calcium 
deposition, which may represent non-yet-calcified plaques, will also be studied. 
The field of research will then be expanded to the entire body: as atherosclerosis is a 
systemic disease, the correlation between calcium content and uptake within plaque and 
trabecular bone will be studied. In fact, a correlation between arterial calcium deposition 
and atherosclerosis has been shown. When a metabolic link between the two systems 
should be confirmed, then targeted bone-active therapies could be tested, to try and 
prevent plaque evolution.  
Finally, FDG and somatostatin receptors will be pitted against each other, to gain knowledge 




Aim 1: To verify whether fluoride uptake in atherosclerotic plaques corresponds to a 
subsequent variation of their calcium content at follow-up studies. To assess whether 
regions of increased tracer uptake within the vessel wall show a higher density score when 
compared to segments without uptake. To ascertain whether focal NaF uptake might signal 
the future insurgence of an arterial plaque. 
 
Aim 2: To test the correlation between plaque and trabecular bone. To do so, plaque 
characteristics will be studied. Bone features will be assessed by employing an in-house 
coded software application, able to identify the trabecular bone in the CT images 
automatically, and to extract the metabolic information from the co-registered PET images. 
 
Aim 3: To study the correlation between glucose intake and expression of somatostatin 
receptors, as a measure of active inflammation, within the arterial plaque. Data will be 
stratified by vessels region and patients’ risk factors. 
  
MATERIALS AND METHODS 
In order to carry out the objectives stated in the “Aims”, patients were recruited 
retrospectively from three different databases and distributed into three different study 
group, each named with a letter (A, B and C for the Aims 1, 2 and 3, respectively). The 
analysis was carried out offline and on anonymized data. In all patients, written informed 
consent was obtained from each patient before the exam, including the permission to use 
pseudonomyzed imaging data for research purpose. Institutional Ethics Committee 
approved the analysis in all cases and the requirement to obtain additional informed 
consent for this specific analysis was waived. 
The populations consisted generally of oncologic patients, affected by confirmed metastatic 
prostate or breast cancer (populations A and B) or by metastatic NET (population C). The 
databases were located and contained data of patients whose examination had been carried 
out at the following nuclear medicine units: 
- Department of Health Sciences (DISSAL), University Hospital “IRCCS-San Martino-
IST”, Genoa, Italy 
- “Duchessa di Galliera” General Hospital, Genoa, Italy 




The population consisted of 51 patients (19 females, mean age 699 years, range 49-82), 
affected by metastatic prostate or breast cancer. Each patient underwent at least two 
consecutive NaF PET/CT examinations; 15 patients (29%) had at least three exams and 7 
patients (14%) had four or more PET/CT. On average PET/CT examinations were spaced 14 
months apart (range 6-40). Exclusion criteria were: history of vasculitis, autoimmune or 
systemic inflammatory disease as well as chemo- or radiotherapy in the 8 weeks preceding 
each PET/CT examination. Patients having baseline and follow-up studies performed with 
different CT protocols or whose PET images were reconstructed with different methods 
were excluded from the analysis. 
Image acquisition and reconstruction 
Patients underwent 18F-NaF PET/CT using two 16 slices PET/CT hybrid systems: (1) Biograph 
16 (Siemens Medical Solutions, Knoxville TN, United States); and (2) Discovery LS (GE 
Medical Systems, Milwaukee, WI, United States). In both cases patients received an 
intravenous bolus injection of 18F-NaF (4.8-5.2 MBq per kilogram of body weight). PET/CT 
acquisition started 60-75 min thereafter, in the meantime the patient was hydrated and 
encouraged to void, as to diminish the unbound tracer fraction. The entire body was 
scanned from vertex to toes in an “arms down” position; emission scan lasted 120’’ per bed 
position. PET raw data were reconstructed by means of ordered subset expectation 
maximization (OSEM, 3 iterations, 16 subsets) and attenuation correction was performed 
using CT data. The transaxial field of view and pixel size of the reconstructed PET images 
were 58.5 cm and 4.57 mm, respectively, with a matrix size of 128 × 128 mm. As per 
standard PET/CT imaging protocol, 16-detector row helical CT scan was performed with non-
diagnostic current and voltage settings (120 Kv, 80 mA), with a gantry rotation speed of 0.5 s 
and table speed of 24 mm per gantry rotation. No contrast medium was injected. The entire 
CT dataset was fused with the 3-dimensional PET images using an integrated software 
interface (Syngo; Siemens Erlangen, Germany). Low dose CT (reconstructed at 4mm thick 
slices) was used for anatomical reference for the localization of vascular calcification. 
Image Analysis 
Images were analyzed at a research workstation using the Horos DICOM viewer (Pixmeo 
Sàrl, Bernex, CH). On each patient, fusion (PET and CT) and CT images of the baseline and of 
the follow up study were opened in parallel. The slice position was synchronized at the 
appearance of the vertex. The images were then scrolled, to identify presence of 
calcification within the abdominal aorta wall. All isolated calcifications (AC) were identified, 
calcifications with evidence of tracer spillover from the vertebrae were excluded (a 
minimum distance of 1 cm from any vertebral body was in all cases required). Also, 
immense, clumped and ring-like calcifications, stretching for more than 5 CT consecutive 
slices, were excluded due to their low likelihood of presenting cellularity capable of tracer 
uptake [33]. On each AC, a VOI was built semi-automatically, using a 3D region-growing 
algorithm (Figure 1). 
 
 Figure 1. VOI creation on arterial plaques. Volumes were created using a region-growing 
algorithm: once set a seeding point, the software toll will generate a VOI by including all 
neighboring voxels above a certain HU threshold. 
In each VOI, mean SUV and mean HU density were computed. Additionally, an Agaton-like 
CS was calculated, using a dedicated Horos plug-in. Mean SUV was normalized for blood pool 
(BP), to account for different uptake time, for different scanners and to adjust for detectors’ 
sensitivity. Blood pool was obtained by manually drawing a 10-slice thick VOI in the inferior 
vena cava, the SUV/BP ratio was defined target-to-background ratio (TBR). 
The same plaque was then identified on the follow-up scan and a similar VOI was 
constructed. Percent difference in HU and CS was calculated and named Delta-HU (DHU%) 
and Delta-CS (DCS%). These two values were in turn normalized for the number of months 
elapsed between scans (NDHU% and NDCS%, respectively). 
Finally, a large VOI, comprising the entire abdominal aorta, was drawn (while maintaining 
the ground rule of keeping a 1 cm distance from the vertebrae) and the BP normalized SUV 
was calculated (TBR). Within the same space, the total CS was calculated, by applying the 
tool to each calcium deposition within the vessel wall and by summing the results. 
Statistical Analysis 
All data are reported as Mean ± SD. Differences between groups were tested using one-way 
analysis of variance, with intergroup comparison afforded using Bonferroni test. Paired T-
Test was used to assess the variation of uptake, HU, and CS in the plaques (test-retest). 
Correlation was tested used bivariate analysis (Pearson’s R as well as by multiple linear 
regression analysis). p values <0.05 were considered as statistically significant. Statistical 





The study included 79 patients with either breast (65%) or prostate (35%) cancer undergoing 
18F-NaF PET/CT scan for suspected bone metastases or for monitoring of known ones.  
Patients were included in the analysis if they presented at least one CT-evident arterial 
calcification (AC) in the infrarenal abdominal aorta. AC was defined as described above (see 
Population A). 
Exclusion criteria were: history of vasculitis, autoimmune or systemic inflammatory disease 
as well as chemo- or radiotherapy in the preceding 8 weeks, as previously proposed. Chronic 
steroid therapy represented an additional exclusion factor. Cardiovascular risk profile was 
assessed in each patient (including age, sex, diabetes, smoking, hypertension, dyslipidemia 
and body mass index). 
35 age- and sex-matched patients, having no evidence of arterial calcifications were 
randomly selected from our pool of 18F-NaF-PET/CT examinations and used as plaque-free 
controls. 
Image Analysis 
Plaque analysis was carried out as described above.  
Bone image analysis was performed semi-automatically according to a previously validated 
method [47]. Briefly, the algorithm identifies the skeleton on CT images assuming that 
compact bone is the structure with the highest radiograph attenuation coefficient in the 
human body. Once it has identified the skeletal border, the program starts the thresholding 
algorithm, which samples a 2-voxel- thick layer and computes its average Hounsfield Unit 
(HU) value. Thereafter, all skeletal voxels having attenuation coefficient equal or above this 
value are considered as compact bone, and the remaining as trabecular bone. This latter 
volume is then voxel-wise multiplied against the PET co-registered data to extract and 
represent bone marrow metabolic activity. For the purpose of the present analysis, thoracic 
and lumbar vertebrae were selected as representative bone regions. 
This above-described segmentation method can tell apart osteoblastic metastases from 
normal trabecular bone [33]. Moreover, the software removes all voxels under a 100 HU 
threshold, effectively excluding lytic metastases. Therefore, it is possible to analyze 
trabecular bone metabolism without the influence of uptake from tumor localizations. 
However, effects due to radioactivity spill-over from nearby lesion or presence of mixed-
type metastases within trabecular bone cannot be denied with utmost security by the 
automated analysis. For this reason, two expert readers reviewed the output images and 
manually removed all bone regions with suspicious metastatic involvement. 
See Figure 2 for a graphical representation of the bone marrow analysis. 
 
Figure 2. Analysis of the trabecular bone activity. A MatLab-based computational tool was 
applied to the PET/CT images. The application identifies and segments the trabecular space 
automatically. It then generates a mask, which is copied onto the PET dataset, allowing the 
extraction of functional information exclusively from the target bone tissue. 
 
Statistical Analysis 
All data are reported as Mean ± SD. Patients with ACs were stratified in three groups 
according to their tercile of mean plaque density: patient with a mean calcification in the 
lower tercile were defined as with “light” calcifications, while those in the middle and upper 
terciles were defined as having “medium” and “heavy” calcifications, respectively. 
Differences between groups were tested using one-way analysis of variance, with intergroup 
comparison afforded using Bonferroni test. Correlation was tested used bivariate analysis 
(Pearson’s R as well as by multiple linear regression analysis. p values <0.05 were considered 
as statistically significant. Statistical analyses were performed using SPSS software Advanced 




Twenty-seven patients (12 males, mean age 69.4 ± 8, range 56-87), affected by metastatic 
NET, were included in the present analysis. Each patient underwent an FDG PET/CT and a 
68Ga-DOTATOC PET/CT within a two-weeks period. At the moment of the first visit, blood 
pressure was measured, and a cardiovascular RF anamnesis was carried out. Cardiovascular 
risk stratification of the scanned patients was performed according to a simplified version of 
the Framingham model (including age, diabetes, smoking, systolic blood pressure BMI [48]. 
In particular, systolic blood pressure values, as well as treatment for hypertension were 
included in the Framingham score computation. Similarly, positive smoking history was 
considered in case of active smoking habit at the time of scan, as well as in case of past 
smoking habits. Finally, no information about severity of diabetes and/or to insulin or other 
treatment for diabetes was taken into account in the computation.  
Exclusion criteria were the same as per the Population A. 
Image Analysis 
In all patients, a large VOI was constructed on the entire aorta, in both the FDG and in the 
68Ga-DOTATOC PET/CTs. Here, SUVmean and SUVmax were computed. These values were 
then normalized for BP, to obtain TBRmax and TBRmean. TBRmean represented the overall 
mean uptake within the vessel wall while TBRmax was used to capture the highest activity, 
which was invariably located within the atherosclerotic plaque. 
Statistical Analysis 
All data are reported as Mean ± SD. Differences between groups were tested using one-way 
analysis of variance, with intergroup comparison afforded using Bonferroni test. Correlation 
was tested used bivariate analysis (Pearson’s R as well as by multiple linear regression 
analysis). p values <0.05 were considered as statistically significant. Statistical analyses were 




Arterial Plaques and whole aorta analysis 
At the first PET/CT mean TBR within the vascular lesions was 2±0.8, while mean HU density 
and mean CS were 240±133 and 180±130. At the moment of the second PET, mean HU had 
increased up to 272±135 (p<0.001 Vs. the first PET) and CS had also increased to 220±274 
(p<0.001 Vs. baseline). Mean TBR was not significantly changed. See Figure 3 for details. 
 
Figure 3. Values of mean HU density and Calcium Score. A significant increase can be 
highlighted at the follow-up PET. ***p<0.001. 
 
Mean DHU% and mean DCS% were 19±20% and 51±59%, respectively; normalized values 
corresponded to 3±2% and 7±8%. A tight and direct correlation was noted between TBR in 
the plaques in the baseline PET and both NDHU% (R=0.67, p<0.01) and NDCS% (R=0,7, 
p<0.001), see Figure 4 for details. 
An even stronger correlation was observed between mean TBR of the whole aorta and the 
total variation in CS in the entire vessel (R=0,85, p<0.001). See Figure 5. 
  
 
Figure 4. Correlation between baseline plaque TBR and calcification indices. 
 
Figure 5. Correlation between baseline whole aorta TBR and total CS. 
  
Gallery of representative plaques 
Global plaque and aortic analysis showed that mean activity within the plaque predicted it 
future calcium content variation. Here, we highlight some representative cases where the 
activity of calcium deposition and the subsequent density variation were visible at PET/CT 
images qualitative observation. 
Active and lightly calcified plaque 
These plaques represent arterial calcium accumulation in their earlier stages. It is therefore 
common to observe a visible bone-seeking tracer accumulation within, as this phenomenon 
reflects the activity of the osteoblast-like cells residing within the plaque. Such lesions 
frequently present a significant variation of calcium content at follow-up. In Figure 6, an 
example of a very lightly calcified arterial wall is presented. At follow-up, activity within the 
atheromatous lesion hat diminished, but the calcium content has markedly increased. 
  
Figure 6. Early stage calcification, progressing at follow-up. At baseline (top panel) focal 
calcification cores, with moderate NaF uptake, are noted (arrowheads). At follow-up 
(bottom panel), tracer uptake has dwindled, but the calcification cores have expanded, and 
calcium density has markedly increased (arrows). 
Mixed Plaque with actively growing segments 
This kind of plaques represent a sort of intermediate stage between early, rapidly growing 
early plaque and the massive, old plaques, which are no longer actively concentrating 
calcium. Here we can see a multi-segment plaque, on its way to becoming a ring-shaped 
plaque, embracing the entire aortic wall. Here we observe some focal tracer uptakes, at the 
edge of major calcium chunks or between two bigger calcified areas. In the same regions, an 
increase in calcium content is observed in the follow-up images. 
 
Figure 7. Mixed-type plaque. Notice the focal increased NaF uptake at the baseline PET (top 
left panel, arrowheads). In the same positions, increase in calcium content is observed and 
the gap between the two plaques on the left side of the aorta is closed (bottom left panel, 
arrows). The right panel show the CT images. 
 
A plaque is born: significance of diffuse uptake 
Non-calcified plaques are lesion that cannot be appreciated by morphological imaging. Their 
lack of calcium content and their lipid core imply a mean HU density which is near to that of 
vessel wall or of luminal blood. However, is some rare occasion, it is possible to capture the 
moment in which a calcified plaque is “born”. In fact, non-calcified lesions represent the 
earlier stages of atheromatosis’ evolution. As described, the chronic inflammation fosters a 
commitment of the mesenchymal cells to the osteoblast line. These bone-forming cells then 
start concentrating and laying calcium onto the plaque. This activity can be registered by 
NaF-PET, either as focal or diffuse tracer uptake within the vascular wall. On follow-up scans, 
it might be possible to witness early cores of calcification, which will then build up the early 
calcified plaque. 
 
Figure 8. Birth of a calcific plaque. In the baseline fusion images (top panel), a mild NaF 
uptake is observed, which delineates the entire left and posterior sides of the abdominal 
aorta. On the follow-up PET/CT, the tracer uptake became much more intensive and diffuse, 
affecting the whole vessels circumference. A lightly calcified spot is now observed 
posteriorly left (bottom panel, arrow). In retrospect, a tiny calcified spot may be observed in 
the baseline scan (arrowhead), however, this bit of calcium is not picked up by the 
algorithm, as it doesn’t reach the 90 HU mark. 
  
Heavily calcified plaques 
This entity is the last stage of arterial calcification. In these plaques, no uptake is observed 
and no significant variation between baseline and follow-up can be demonstrated (data not 
shown). These lesions tend to display HU values averaging near the upper limit of the scale 
and close to the one of compact bone; the encase the whole arterial volume and stretch for 
numerous CT slices. 
  
POPULATION B 
Characteristics of the study population 
Out of the 79 study patients, 60 (76%) had evidence of bone localizations while 19 
(24%) had no highlightable metastases. Table 1 lists the main characteristics of the 
study population, including a comparison of patients with and without bone metastases. 
The prevalence of major cardiovascular risk factors and medications did not differ 
between these groups, except for a slightly higher prevalence of diabetes in those 
without bone metastases (50% vs. 21% in those with metastases, p=0.03). The only 
significant difference in 18F-NaF PET/CT-derived parameters was a higher aortic mean 
HU in those patients with evidence of bone metastases (241.8±58.7 vs. 241.8±58.7 in 
those without metastases, p=0.03). There were no other differences in bone-related 
parameters. 
On the basis of the tercile stratification, the “heavy” and “medium” calcifications’ groups 
counted 26 patients each and the remaining 27 patients were placed in the “light” 
calcification group. 
 




























Women 65% 89% 57% 45% 0.009 NS 
Previous chemotherapy 41% 11% 51% 62% 0.002 0.045 
Previous radiotherapy 55% 32% 63% 65% 0.02 NS 
Previous chemo- or 
radiotherapy 
63% 32% 73% 81% 0.001 
0.039 
Previous chemo- and 
radiotherapy 
29% 11% 35% 43% 0.04 
NS 





Obese (body mass 
index≥30 kg/m2) 
9% 16% 7% 6% NS 
NS 
Smoking history 58% 57% 58% N/A NS - 
Hypertension 67% 69% 65% N/A NS - 
Antihypertensive 
medications 
66% 77% 61% N/A NS 
- 
Dyslipidemia 46% 43% 47% N/A NS - 
Lipid-lowering 
medications 
25% 31% 24% N/A NS 
- 
Diabetes 29% 50% 21% N/A 0.03 - 
Bisphosphonates 7% 0% 7% N/A NS - 
Warfarin 7% 0% 7% N/A NS - 
Proton pump inhibitors 31% 29% 31% N/A NS - 
 
Uptake and calcification Indices  
In patients with ACs, mean TBR in the trabecular bone was 6.2±3.9 and mean trabecular 
bone density was 137±25 HU.  The mean TBR of all aortic plaques was 1.9±1.2, with a 
mean HU density of 227±61.  Control patients without ACs had a markedly higher 
vertebral density (160±14 HU, p<0.001 Vs. patients with plaques) and a slightly higher 
mineral metabolism (TBR 8.4±3.4, p<0.05 vs patients with plaques). Among the patients 
with ACs, a progressive reduction in mineral metabolism as well as in trabecular bone 
density can be observed when comparing the three subgroups, whereas patients with 
“heavy” calcifications show significantly reduced values in comparison with these with 
“light” arterial calcium deposits.  
In fact, mean trabecular TBR values were 8.3±4, 4.5±2,1 and 3.5±1.8 in light, medium 
and heavy calcifications’ groups, respectively (p<0.05 for light Vs. medium and p<0.01 
for light Vs. heavy). Similarly, mean trabecular HU was 143±19, 127±26 and 119±18 in 
the three groups, respectively (p<0.01 for light Vs. heavy). Finally, uptake intensity 
within the plaque dwindled when progressing from heavy to light calcifications (TBR: 
2.1±1; 1.8±1 and 1.4±0,6 for light, medium and heavy calcifications, respectively, p<0.05 
for medium Vs. heavy and p<0.01 for light Vs. heavy). 
 See Figure 9-10 and Table 2 for details. 
 
Figure 9. Density trabecular bone and in the aortic plaque. In the three top panels 
are displayed low-dose CT images depicting examples of typical “light”, “medium” and 
“heavy” plaques. Directly below (middle panels) are displayed CT slices of the trabecular 
bone from the same patients.  
After terciles stratification according to mean plaque density, subjects with a higher 




Figure 10. Mineral metabolic activity in patients and controls. The histograms 
depict the target-to-background ratio of subjects with a ACs and of controls in trabecular 
bone (upper) and the corresponding value within the plaques. Subjects with ACs had a 
lower TBR than controls; however, this metabolic decrease was circumscribed to 
patients with medium and heavy calcifications. Likewise, plaque TBR was higher in less 
heavily calcified plaques. 
 




























BONE VARIABLES  
Bone mean HU  137±25 135±31 126±18 160.3±14 NS <0.001 
Bone mean TBR 6.2 ±3.9 5.9 ±2 6.4 ±4.5 8.4 ±3.8 NS 0.034 
       
AORTIC PLAQUE VARIABLES  
Aortic mean HU 227±71 206±65 245±59 - 0.026 - 
Aortic mean TBR 1.9 ±1.2 1.9 ±1.4 2 ±1.1 - NS - 
Infrarenal aortic 
diameter, mm 
18.6 ±4.4 18.1 ±1.6 18.8 ±4.9 - NS - 
 
Interaction between plaque and bone 
Mean plaque density showed an inverse association with vertebral HU density (R=-0.56, 
p<0.01, Figure 11). In opposition, no correlation between age and HU density was 
observed. Conversely, plaque and trabecular bone TBR were directly and closely 
correlated (R=0.63 and p<0.001, Figure 11).  
Arterial plaque HU density displayed an inverse correlation with its own TBR (R= -0.42, 
p<0.05, Figure 12), as well as with lumbar vertebrae TBR (R= -0.47, p<0.01, Figure 12).  
 
Figure 11. Correlation between vertebral density and plaque features. A higher 
plaque density was associated to a lower trabecular density; conversely, TBR in the AC 




Figure 12. Correlation between plaque and trabecular mineral metabolism. 
Patients with thicker arterial calcifications showed a reduced mineral metabolism 
within the plaque itself and in the trabecular bone. 
 
Multiple regression analysis of plaque density and metabolism 
At univariate analysis, mean HU density of aortic plaque was not predicted by any of the 
cardiovascular risk factor or by age; conversely, it was related to its own TBR 
(p=<0.001) as well as by trabecular bone TBR (see Table 3 for details). Mean vertebral 
density was related only to plaque density (p<0.05); conversely age, use of 
bisphosphonates and previous radio/chemotherapy had no influence on vertebral 
status (Table 4). 
Table 3: Multiple Regression Analysis of Parameter affecting aortic plaque density (HU) 
  Standardized Coefficient   95% Confidence Interval 




            
Age 0.168 1.503 NS -0.407 2.91 
Gender -0.033 -0.296 NS -32.12 23.813 
Smoking History -0.108 -0.929 NS -29.935 10.896 
Hypertension 0.032 0.271 NS -23.938 31.486 
Diabetes 0.025 0.21 NS -28.048 34.648 
Dyslipidaemia 0.061 0.51 NS -20.355 34.339 
Aortic Plaques TBR  -0.401 -3.786 <0.001 -43.009 -13.351 
Mean trabecular TBR -0.558 -3.863 <0.001 -14.966 -4.641 
 
Table 4: Multiple Regression Analysis of Parameter influencing Vertebral Density (HU) 
 
Variable Beta t Sig. 





Chemotherapy -.154 -.685 NS -31.308 16.077 
Radiotherapy .370 1.658 NS -4.738 37.925 
Bisphosphonates -.215 -1.188 NS -68.115 19.372 
BMI .342 1.643 NS -.711 5.489 
Age -.045 -.220 NS -1.419 1.154 
Gender .247 1.15 NS -0.856 1.152 
AC Density (HU) -.546 -2.671 .014 -.398 -.051 
Mean trabecular TBR -.050 -.214 NS -3.347 2.737 




General Population characteristics 
On average, the cardiovascular risk score was 12,5±9,1% (range 2,1% - 35,7%). Among the 
27 patients 11 (41%) were classified as having a low CV risk (30-years MACE-likelihood 
<10%), 10 (37%) were at medium risk (MACE risk between 10% and 20%) and six (22%) 
presented a high CV risk (acute events likelihood >20%). 
Mean systolic blood pressure was 135±23 mmHg and 22 subjects (81%) were on 
antihypertensive medications. Mean BMI was 29,2±5,6. Eight patients (29%) were 
active smokers at the time of the first visit. Twelve patients (44%) suffered from 
diabetes mellitus (DM). 
 
Uptake value of FDG and SSR-tracer 
Average TBRmean was not significantly different between FDG and 68Ga-DOTATOC 
(1,2±0,5 Vs. 0,8±0,6, respectively p= ns). Conversely, the mean of TBRmax was 
significantly higher in 68Ga-DOTATOC PET, when compared to FDG (5,7±3,1 Vs. 2±1,2, 
p<0.01). See Figure 13 for details. 
A tight and direct correlation was noted between FDG TBRmean and CV risk score 
(R=0.82, p<0.001), as well as between 68Ga-DOTATOC TBRmean and CV risk score 
(R=0.81, p<0.001). See Figure 14. 
Finally, average TBRmax of FDG was not significantly different when considering 
patients with DM versus the remaining ones (2.1±0.5 Vs. 1.8±0.4, p=ns); however, 
TBRmax of 68Ga-DOTATOC was slightly higher in DM patients when compared to the 
non-diabetic ones (6±2.1 Vs. 4,9±0,9, p<0.05). Details are to be found in Figure 15. 
 
Figure 13. Average uptake within the vascular VOI. **p<0.01 
 
Figure 14. Correlation between mean vascular uptake and CV risk score. 
 
Figure 15. Uptake in diabetics and non-diabetics. *p<0.05 
  
Gallery of representative plaques 
FDG-positive, 68Ga-DOTATOC-negative plaques 
FDG uptake is a common finding in growing arterial calcifications. Such an increased tracer 
distribution is prevalently observed within plaques presenting a very thin calcification, like 
the one displayed in Figure 16. Here, we can observe a diffuse FDG activity, which is diffused 
within the entire calcification ring, and a very faint SSR-tracer uptake, which localizes 
predominantly in the thinner posterior segments. 
 
Figure 16. FDG-positive (upper panels), SSR-tracer negative (lower panels) arterial plaque. 
 
68Ga-DOTATOC-positive, FDG-negative plaques 
This type of plaque presents an intensive (often focal) somatostatin-receptor tracer uptake 
while displaying no visible glucose metabolism. Comparably to the FDG-positive plaques, 
these arterial calcifications are thin and mildly dense in nature; an example of such plaque 
can be seen in Figure 17. Here, a mild FDG uptake can be observed in the right-side plaques. 
However, the focal 68Ga-DOTATOC uptake, which is observed in the right-posterior plaque, 
present a markedly higher tracer intensity. 
 
Figure 17. FDG-negative (upper panels), Ga-DOTATOC-positive (lower panels) plaque. 
 
Tracer-negative plaques 
In opposition to the above-described cases, some plaques might present neither FDG nor 
SSR-tracer uptake. In most cases, such arterial calcifications are in a very advanced stage and 
present a high attenuation value. As discussed, a tracer substance can be trapped within a 
tissue only in the presence of an adequate cellularity or of active metabolism caused by 
ongoing processes. End-stage calcifications do not display these features. However, they 
could progress over time, owing to passive calcification mechanisms such as calcium salt 
precipitation in the presence of damaged endothelium. 
 
Figure 18. Advanced plaque, not showing any tracer uptake. 
  
DISCUSSION 
The present work reports the analysis of plaque metabolism, conducted used three of the 
most widely available PET radiotracers and aimed at determining the significance of 
radiopharmaceutical uptake within the calcified lesion. Our results show that sodium 
fluoride uptake, tracing osteoblast activity within the atherosclerotic microenvironment, is a 
marker of subsequent evolution of the plaque calcium content. Moreover, we have shown 
that both glucose metabolism and density of somatostatin receptors within vessel walls are 
linked to cardiovascular risk, however, SSR2 imaging might be apter in capturing the plaque 
inflammation in diabetic patients. 
In the following paragraphs, we are going to discuss these results in light of the existing 
literature evidence. Moreover, we will try to analyze the possible future direction of the 
plaque imaging research. 
 
Fluoride PET: a key to understanding the plaque mineral turnover mechanisms 
18F-Sodium fluoride represents the most ancient PET tracer [49]. First introduced in the 
sixties, it was later dropped for 99Tc-based agents, which featured lower costs and a more 
favorable absorbed-dose profile [50]. The relatively recent introduction of hybrid PET/CT 
scanners contributed to re-awakening the interest in this tracer, which presents a higher 
sensitivity when compared to single-photon bone-seeking agents [51]. Recent progress in 
the PET technique, including 3D acquisition, time-of-flight photon origin detection, point 
spread function, and others, enable the characterization of smaller structures, such as the 
atherosclerotic plaque [41]. To this point, research on the field has been pointed in 
characterizing the uptake patterns within the plaque or within the vessels [33; 45; 52] or in 
defining the culprit plaque after an acute event [46]. In particular, coronary plaques that 
have undergone rupture and that have caused myocardial infarction, present an increased 
fluoride uptake. This feature is not surprising, as the acute inflammation and the reparative 
process foster an increased mineral metabolism in the area. More interestingly, the authors 
have found a correlation between high-risk plaque characteristics in patients with stable 
angina and radioactive tracer uptake, a result that was also confirmed by further studies 
[53]. However, it is not known whether patients with stable angina and NaF-positive plaques 
did present acute infarction in their subsequent clinical history. It might be as well possible 
that the uptake was caused by continuous calcium deposition within the growing plaque, 
which in turn caused the clinical symptoms. As it is, there are not enough data to be able to 
recommend an invasive procedure, having the purpose of preventing later cardiovascular 
events, in patients with elevated fluoride uptake within a coronary plaque. 
For these reasons, in the current work, we focused on the slow-and-steady nature of plaque 
growth. If the atherosclerosis is a process that spans over decades, it might make sense to 
check scans that are spaced months or years apart, to see if anything changes. Our results 
confirm the hypothesis of slow growth of the plaques: this phenomenon was observed 
mainly in those lesions with high sodium fluoride uptake and correlated with the intensity of 
tracer accumulation. 
Similar results have been reported by Dweck and colleagues, who detected a tight positive 
correlation between fluoride uptake and an increase of calcium score in a segment affected 
by aortic stenosis [54]. Interestingly, after removing from the computation those plaques, 
which presented a more-advanced calcification pattern, the correlation gained further 
significance. This finding supports the hypothesis that NaF-PET should be directed in 
analyzing the early-stage calcification, showing active deposition mechanisms. In another 
study by Li and colleagues, a trend towards calcification increase was found, which was 
associated with increasing NaF and decreasing FDG uptake: these data could support the 
hypothesis that inflammation is prevalent in the earliest, non-calcified plaque phases, while 
increased mineral turnover prevails later on [55]. Ishiwata and co-workers found an 
association between background-corrected fluoride uptake and the increase of both volume 
and calcification score of arterial plaques [56]. They did not however identify a correlation 
between tracer uptake and HU variation. However, they had a smaller population and they 
did not correct for the time elapsed between the two scans: this point is relevant, as a 
greater increase of calcium is expected when more month since the baseline scans have 
elapsed. Furthermore, they work analyzed the link between focal NaF accumulation and 
appearance of calcium in follow up scans: this was the case in about one-fifth of the cases. It 
must be considered that their study population also included non-oncologic patients, who 
presumably received a lower tracer activity and who could have been younger than the rest 
of the population. Moreover, a mean follow-up of one year might be insufficient to witness 
visible calcification in the hot spot area. A HU analysis of the region might have served this 
purpose. 
Overall, existing literature is currently not plentiful, yet it hints towards a major role of 
fluoride accumulation in predicting subsequent plaque evolution. The relative inconsistency 
of some results might be caused by the generally small sizes of the examined samples and by 
the difference in methodology. However, almost all authors have applied some sort of 
background correction, which led to reproducible results in term of target-to-background 
ratios across all studies. On the other hand, follow-up studies were carried out at different 
intervals. This is understandable, given that the execution of PET/CT has always been driven 
by clinical need and prospective studies with ethical clearance to apply a radioactive 
substance to patients without recognized Fluoride-PET indication are non-existent. However, 
time normalization should always be applied. Also, plaque density should be measured with 
a recognized algorithm in all cases (i.e. the Agaston score), so as to account for plaque 
volume and density the at the same time. 
 
The interaction between bone and plaque: a new window into atherosclerosis’ 
pathophysiology? 
The existence of a link between atherosclerosis’ progression and bone was first postulated 
on the basis of the observation that subjects with massive arterial calcifications also showed 
a high prevalence of osteoporosis [57; 58]. However, this was considered mostly a 
coincidence, as both conditions are fairly common in advanced age. However, our data 
showed that an inverse correlation between calcification density and mean trabecular bone 
HU exists and that age does not play a relevant role in this association. Moreover, fluoride 
activity within the bone, which mirrors the density and the activity of the bone-forming 
matrix, is reduced in patients with plaques compared to those without plaques, and it is 
further reduced in those bearing “heavy” calcifications. Two consequences may be inferred 
from this observation: that patients with arterial calcifications should be screened, and 
eventually treated, for osteoporosis; and that observing the bone matrix could grant an 
easy-access window onto the atheromatosis’ pathophysiology. Since we have a number of 
effective treatments against osteoporosis, it might be conceivable that such medications 
could be effective against plaque progression as well. This hypothesis has been to this date 
barely investigated: the only available data originate from a subpopulation of the FREEDOM 
study, where the effect of a long-lasting Denosumab (specific RANKL-antibody) therapy on 
CV risk and calcification progression were tested against placebo [59]. The study failed to 
demonstrate a CV benefit of the drug over a three-year period (a non-significant 2% risk 
reduction of cardiovascular events was observed). However, this study included only female 
patients, with 91% of patients being older than 70 years. Moreover, the follow-up period 
was limited to three years. Therefore, it is unknown whether this approach would be 
effective if applied to the male gender, if started at an earlier age or if its effects are 
evaluated with a more extended follow-up. In fact, considering the long-term course of the 
atherosclerotic disease, a continuous treatment might be in order to achieve full effect. Even 
if the anti-resorption therapy should prove unsuccessful in delimiting plaque growth, it could 
nonetheless be used to prevent bone loss and consequently to limit the fracture risk in these 
patients. 
Comparing these data to the existing literature is challenging, for they are based on an in-
house built software application, which has been specifically designed for the scope of 
isolating the signal originating from the trabecular bone. As a matter of fact, a decreased HU 
density within the trabecular bone is a common finding in patients suffering from 
oncological disorders such as CLL, multiple myeloma and metastatic castration-resistant 
prostate cancer [60-62]. However, bone HU density was significantly different among the 
different plaque thickness groups, while no differences were observed between patients 
with metastatic and non-metastatic disease. 
In conclusion, these data confirm that arterial is not an isolated epiphenomenon of plaque 
progression within the arterial wall, but instead might involve and affect multiple systems, 
among which trabecular bone, as the main calcium storage of the human body, might play a 
prominent role. 
 
Detecting plaque inflammation: going sure-fire or going specific 
Our data, in keeping with those of the existing literature, demonstrated a direct correlation 
between FDG and SSR-tracer uptake and estimated cardiovascular risk [63]. This is explained 
by the fact that the presence of risk factors promotes atherosclerosis, which is in turn 
associated with inflammation, which is picked up by glucose metabolism or SSR imaging. 
However, arterial hotspots were more easily detected by 68Ga-DOTATOC rather than by 
FDG imaging. This phenomenon depends on the different specificity of the two imaging 
techniques: while FDG uptake might be moderately increased in almost any kind of 
inflammation-related cell, SSR2 are only expressed on the surface of activated macrophages 
[38]. Moreover, we demonstrated a higher 68Ga-DOTATOC uptake in diabetic patients: this 
is probably caused by the insulin-resistance mechanisms, which inhibit GLUT expression and 
cause an increase of circulating glucose, which then competes with FDG for tissue uptake. It 
follows that, when inflammation is to be tracked, 68Ga-DOTATOC should be the tracer of 
choice. On the other hand, FDG might be employed in those centers that do not perform SSR 
imaging on a regular basis. 
 
A glance into the future 
 
Using PET-based tracer could have a number of applications in patients suffering from 
atherosclerosis. Thanks to the dual morphological and functional nature of PET/CT imaging, 
it would be conceivable to employ a whole-arterial or aimed examination (e.g. on the 
coronary district) to assess the extension, the density and the metabolism of the 
atherosclerotic disease. In this setting reducing the tracer activity and employing low-dose 
CT protocols could contribute to reducing the absorbed dose. It would be then possible to 
track the development of the disease by performing serial examinations. The compliance of 
the patient could be tested by using this method. In fact, it could be synergic in offering 
additional motivation (for instance in BMI reduction, or in meeting the blood pressure and 
glycemia goals) in high-risk patients. In fact, the patient would not solely be aware of the 
improvement of the clinical score (BMI, blood sugar and so on) but he or she could 
potentially see on the radiological monitor his or her own arterial plaque losing “steam” as 
the risk-reduction strategy kicks in. Should the patient suffer a MACE, it would be possible to 
analyze the coronary plaque status retrospectively, allowing, over time, to build up a 
database of high-risk plaques, which could allow in pre-empting such events. New 
computational application, namely machine learning and AI, could read these data and learn 
to recognize the high-risk pattern. 
Moreover, novel or existing agents could be tested, and their efficacy monitored with these 
methods. Here, preclinical disease models might come into play. Also, bone-active treatment 
could be tested within this framework. 
When considering human studies, it is important to bear in mind that the natural history of a 
plaque spans, in most cases, over decades. With this information in mind, studies aimed at 
testing the efficacy of new treatment should be conceived so as to follow up the patient for 
an adequate stretch of time, before any conclusion can be drawn. 
  
CONCLUSIONS 
Radioisotope plaque imaging is a multi-faceted and promising field of research, which uses 
the newest available imaging methods to answer ancient questions, which regard the 
accurate risk estimation in the cardiovascular patient. Using these methods, inflammation 
and bone-forming activity can be identified and tracked within the atherosclerotic plaque, 
and a wide array of relevant information can be obtained. 
In order to employ these techniques correctly, a standardization of the acquisition and 
analysis methods is urgently needed. Prospective randomized studied are also required to 
move this field from the purely academic area onto a patient-tailored diagnostic approach, 
having the potential to improve the quality of the cardiovascular diagnostic and to 
ameliorate the patients’ survival and quality of life. 
  
COMPLIANCE WITH ETHICAL REGULATIONS 
All patients described in the present analyses signed an informed consent, which was 
approved by the Regional Review Board, before undergoing PET/CT imaging. This consent 
included the possibility of utilization of anonymized data in the framework of retrospective 
studies. Therefore, case-specific requirement for an approbation from the Ethics Committee 
was waived. Analysis was performed on an offline station, patients’ names were 
pseudonomyzed. No study with animals was conducted.  
  
ACKNOWLEDGMENTS 
I would like to thank my family for the relentless support. 
My heartfelt thanks go to the Prof. Sambuceti and to the Prof. Bagnasco for encouraging me 
to pursue this ambitious objective and to accept an important new challenge. 
Special thanks to Dr. Piccardo and to Prof. Ciramiello for setting their own patient database 





1 Laslett LJ, Alagona P, Jr., Clark BA, 3rd et al (2012) The worldwide environment of 
cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report 
from the American College of Cardiology. J Am Coll Cardiol 60:S1-49 
2 Collaborators GBDCoD (2017) Global, regional, and national age-sex specific mortality 
for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of 
Disease Study 2016. Lancet 390:1151-1210 
3 Mortality GBD, Causes of Death C (2016) Global, regional, and national life 
expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 
1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 
388:1459-1544 
4 Foreman KJ, Marquez N, Dolgert A et al (2018) Forecasting life expectancy, years of 
life lost, and all-cause and cause-specific mortality for 250 causes of death: reference 
and alternative scenarios for 2016-40 for 195 countries and territories. Lancet 
392:2052-2090 
5 Chen S, Kuhn M, Prettner K, Bloom DE (2018) The macroeconomic burden of 
noncommunicable diseases in the United States: Estimates and projections. PLoS One 
13:e0206702 
6 Gheorghe A, Griffiths U, Murphy A, Legido-Quigley H, Lamptey P, Perel P (2018) The 
economic burden of cardiovascular disease and hypertension in low- and middle-
income countries: a systematic review. BMC Public Health 18:975 
7 Kannel WB, McGee D, Gordon T (1976) A general cardiovascular risk profile: the 
Framingham Study. Am J Cardiol 38:46-51 
8 Silva DR, Werneck AO, Collings PJ et al (2017) Family history of cardiovascular disease 
and parental lifestyle behaviors are associated with offspring cardiovascular disease 
risk markers in childhood. Am J Hum Biol 29 
9 D'Agostino RB, Sr., Vasan RS, Pencina MJ et al (2008) General cardiovascular risk 
profile for use in primary care: the Framingham Heart Study. Circulation 117:743-753 
10 Nesto RW, Phillips RT (1986) Asymptomatic myocardial ischemia in diabetic patients. 
Am J Med 80:40-47 
11 Kameyama M, Fushimi H, Udaka F (1994) Diabetes mellitus and cerebral vascular 
disease. Diabetes Res Clin Pract 24 Suppl:S205-208 
12 Sakakura K, Nakano M, Otsuka F, Ladich E, Kolodgie FD, Virmani R (2013) 
Pathophysiology of atherosclerosis plaque progression. Heart Lung Circ 22:399-411 
13 Otsuka F, Kramer MC, Woudstra P et al (2015) Natural progression of atherosclerosis 
from pathologic intimal thickening to late fibroatheroma in human coronary arteries: 
A pathology study. Atherosclerosis 241:772-782 
14 Webber BJ, Seguin PG, Burnett DG, Clark LL, Otto JL (2012) Prevalence of and risk 
factors for autopsy-determined atherosclerosis among US service members, 2001-
2011. JAMA 308:2577-2583 
15 Hong YM (2010) Atherosclerotic cardiovascular disease beginning in childhood. 
Korean Circ J 40:1-9 
16 Kligfield P, Lauer MS (2006) Exercise electrocardiogram testing: beyond the ST 
segment. Circulation 114:2070-2082 
17 Gibbons RJ, Balady GJ, Bricker JT et al (2002) ACC/AHA 2002 guideline update for 
exercise testing: summary article. A report of the American College of 
Cardiology/American Heart Association Task Force on Practice Guidelines 
(Committee to Update the 1997 Exercise Testing Guidelines). J Am Coll Cardiol 
40:1531-1540 
18 Maddahi J, Kiat H, Van Train KF et al (1990) Myocardial perfusion imaging with 
technetium-99m sestamibi SPECT in the evaluation of coronary artery disease. Am J 
Cardiol 66:55E-62E 
19 Manda YR, Baradhi KM (2018) Cardiac Catheterization, Risks and 
ComplicationsStatPearls, Treasure Island (FL) 
20 Jang IK, Bouma BE, Kang DH et al (2002) Visualization of coronary atherosclerotic 
plaques in patients using optical coherence tomography: comparison with 
intravascular ultrasound. J Am Coll Cardiol 39:604-609 
21 Neves PO, Andrade J, Moncao H (2017) Coronary artery calcium score: current status. 
Radiol Bras 50:182-189 
22 Greenland P, Bonow RO, Brundage BH et al (2007) ACCF/AHA 2007 clinical expert 
consensus document on coronary artery calcium scoring by computed tomography in 
global cardiovascular risk assessment and in evaluation of patients with chest pain: a 
report of the American College of Cardiology Foundation Clinical Expert Consensus 
Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus 
Document on Electron Beam Computed Tomography) developed in collaboration 
with the Society of Atherosclerosis Imaging and Prevention and the Society of 
Cardiovascular Computed Tomography. J Am Coll Cardiol 49:378-402 
23 Hou ZH, Lu B, Gao Y et al (2012) Prognostic value of coronary CT angiography and 
calcium score for major adverse cardiac events in outpatients. JACC Cardiovasc 
Imaging 5:990-999 
24 Arbab-Zadeh A, Miller JM, Rochitte CE et al (2012) Diagnostic accuracy of computed 
tomography coronary angiography according to pre-test probability of coronary 
artery disease and severity of coronary arterial calcification. The CORE-64 (Coronary 
Artery Evaluation Using 64-Row Multidetector Computed Tomography Angiography) 
International Multicenter Study. J Am Coll Cardiol 59:379-387 
25 Doherty TM, Fitzpatrick LA, Inoue D et al (2004) Molecular, endocrine, and genetic 
mechanisms of arterial calcification. Endocr Rev 25:629-672 
26 Lloyd-Jones DM, Larson MG, Beiser A, Levy D (1999) Lifetime risk of developing 
coronary heart disease. Lancet 353:89-92 
27 Libby P (2001) Current concepts of the pathogenesis of the acute coronary 
syndromes. Circulation 104:365-372 
28 Qu W, Le TT, Azen SP et al (2003) Value of coronary artery calcium scanning by 
computed tomography for predicting coronary heart disease in diabetic subjects. 
Diabetes Care 26:905-910 
29 Faxon DP, Fuster V, Libby P et al (2004) Atherosclerotic Vascular Disease Conference: 
Writing Group III: pathophysiology. Circulation 109:2617-2625 
30 Libby P (2002) Inflammation in atherosclerosis. Nature 420:868-874 
31 Rivard A, Andres V (2000) Vascular smooth muscle cell proliferation in the 
pathogenesis of atherosclerotic cardiovascular diseases. Histol Histopathol 15:557-
571 
32 Doherty TM, Asotra K, Fitzpatrick LA et al (2003) Calcification in atherosclerosis: bone 
biology and chronic inflammation at the arterial crossroads. Proc Natl Acad Sci U S A 
100:11201-11206 
33 Fiz F, Morbelli S, Piccardo A et al (2015) (1)(8)F-NaF Uptake by Atherosclerotic Plaque 
on PET/CT Imaging: Inverse Correlation Between Calcification Density and Mineral 
Metabolic Activity. J Nucl Med 56:1019-1023 
34 Shah PK, Galis ZS (2001) Matrix metalloproteinase hypothesis of plaque rupture: 
players keep piling up but questions remain. Circulation 104:1878-1880 
35 Silvera SS, Aidi HE, Rudd JH et al (2009) Multimodality imaging of atherosclerotic 
plaque activity and composition using FDG-PET/CT and MRI in carotid and femoral 
arteries. Atherosclerosis 207:139-143 
36 Davies JR, Izquierdo-Garcia D, Rudd JH et al (2010) FDG-PET can distinguish inflamed 
from non-inflamed plaque in an animal model of atherosclerosis. Int J Cardiovasc 
Imaging 26:41-48 
37 Tarkin JM, Joshi FR, Rudd JH (2014) PET imaging of inflammation in atherosclerosis. 
Nat Rev Cardiol 11:443-457 
38 Tarkin JM, Joshi FR, Evans NR et al (2017) Detection of Atherosclerotic Inflammation 
by (68)Ga-DOTATATE PET Compared to [(18)F]FDG PET Imaging. J Am Coll Cardiol 
69:1774-1791 
39 Wan MYS, Endozo R, Michopoulou S et al (2017) PET/CT Imaging of Unstable Carotid 
Plaque with (68)Ga-Labeled Somatostatin Receptor Ligand. J Nucl Med 58:774-780 
40 Derlin T, Wisotzki C, Richter U et al (2011) In vivo imaging of mineral deposition in 
carotid plaque using 18F-sodium fluoride PET/CT: correlation with atherogenic risk 
factors. J Nucl Med 52:362-368 
41 Derlin T, Richter U, Bannas P et al (2010) Feasibility of 18F-sodium fluoride PET/CT for 
imaging of atherosclerotic plaque. J Nucl Med 51:862-865 
42 Derlin T, Toth Z, Papp L et al (2011) Correlation of inflammation assessed by 18F-FDG 
PET, active mineral deposition assessed by 18F-fluoride PET, and vascular 
calcification in atherosclerotic plaque: a dual-tracer PET/CT study. J Nucl Med 
52:1020-1027 
43 George RT (2012) 18F-sodium fluoride positron emission tomography: an in vivo 
window into coronary atherosclerotic plaque biology. J Am Coll Cardiol 59:1549-1550 
44 Fiz F, Morbelli S, Bauckneht M et al (2016) Correlation between thoracic aorta 18F-
natrium fluoride uptake and cardiovascular risk. World J Radiol 8:82-89 
45 Morbelli S, Fiz F, Piccardo A et al (2014) Divergent determinants of 18F-NaF uptake 
and visible calcium deposition in large arteries: relationship with Framingham risk 
score. Int J Cardiovasc Imaging 30:439-447 
46 Joshi NV, Vesey AT, Williams MC et al (2014) 18F-fluoride positron emission 
tomography for identification of ruptured and high-risk coronary atherosclerotic 
plaques: a prospective clinical trial. Lancet 383:705-713 
47 Sambuceti G, Brignone M, Marini C et al (2012) Estimating the whole bone-marrow 
asset in humans by a computational approach to integrated PET/CT imaging. Eur J 
Nucl Med Mol Imaging 39:1326-1338 
48 Pencina MJ, D'Agostino RB, Sr., Larson MG, Massaro JM, Vasan RS (2009) Predicting 
the 30-year risk of cardiovascular disease: the framingham heart study. Circulation 
119:3078-3084 
49 Ackerhalt RE, Blau M, Bakshi S, Sondel JA (1974) A comparative study of three 
99mTc-labeled phosphorus compounds and 18F-fluoride for skeletal imaging. J Nucl 
Med 15:1153-1157 
50 Thrall JH (1976) Technetium-99m labeled agents for skeletal imaging. CRC Crit Rev 
Clin Radiol Nucl Med 8:1-31 
51 Minamimoto R, Loening A, Jamali M et al (2015) Prospective Comparison of 99mTc-
MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in 
Patients with Breast and Prostate Cancer. J Nucl Med 56:1862-1868 
52 Dweck MR, Chow MW, Joshi NV et al (2012) Coronary arterial 18F-sodium fluoride 
uptake: a novel marker of plaque biology. J Am Coll Cardiol 59:1539-1548 
53 Lee JM, Bang JI, Koo BK et al (2017) Clinical Relevance of (18)F-Sodium Fluoride 
Positron-Emission Tomography in Noninvasive Identification of High-Risk Plaque in 
Patients With Coronary Artery Disease. Circ Cardiovasc Imaging 10 
54 Dweck MR, Jenkins WS, Vesey AT et al (2014) 18F-sodium fluoride uptake is a marker 
of active calcification and disease progression in patients with aortic stenosis. Circ 
Cardiovasc Imaging 7:371-378 
55 Li X, Heber D, Cal-Gonzalez J et al (2017) Association Between Osteogenesis and 
Inflammation During the Progression of Calcified Plaque Evaluated by (18)F-Fluoride 
and (18)F-FDG. J Nucl Med 58:968-974 
56 Ishiwata Y, Kaneta T, Nawata S, Hino-Shishikura A, Yoshida K, Inoue T (2017) 
Quantification of temporal changes in calcium score in active atherosclerotic plaque 
in major vessels by (18)F-sodium fluoride PET/CT. Eur J Nucl Med Mol Imaging 
44:1529-1537 
57 Bagger YZ, Tanko LB, Alexandersen P, Qin G, Christiansen C, Prospective 
Epidemiological Risk Factors Study G (2006) Radiographic measure of aorta 
calcification is a site-specific predictor of bone loss and fracture risk at the hip. J 
Intern Med 259:598-605 
58 Farhat GN, Newman AB, Sutton-Tyrrell K et al (2007) The association of bone mineral 
density measures with incident cardiovascular disease in older adults. Osteoporos Int 
18:999-1008 
59 Samelson EJ, Miller PD, Christiansen C et al (2014) RANKL inhibition with denosumab 
does not influence 3-year progression of aortic calcification or incidence of adverse 
cardiovascular events in postmenopausal women with osteoporosis and high 
cardiovascular risk. J Bone Miner Res 29:450-457 
60 Fiz F, Marini C, Campi C et al (2015) Allogeneic cell transplant expands bone marrow 
distribution by colonizing previously abandoned areas: an FDG PET/CT analysis. Blood 
125:4095-4102 
61 Fiz F, Marini C, Piva R et al (2014) Adult advanced chronic lymphocytic leukemia: 
computational analysis of whole-body CT documents a bone structure alteration. 
Radiology 271:805-813 
62 Fiz F, Sahbai S, Campi C et al (2017) Tumor Burden and Intraosseous Metabolic 
Activity as Predictors of Bone Marrow Failure during Radioisotope Therapy in 
Metastasized Prostate Cancer Patients. Biomed Res Int 2017:3905216 
63 Pasha AK, Moghbel M, Saboury B et al (2015) Effects of age and cardiovascular risk 
factors on (18)F-FDG PET/CT quantification of atherosclerosis in the aorta and 
peripheral arteries. Hell J Nucl Med 18:5-10 
 
